| 1 |
34181204 | Cost Effectiveness of Gemtuzumab Ozogamicin in the First-Line Treatment of Acute Myeloid Leukaemia in the UK. | 2021 Dec |
1 |
| 2 |
34572794 | Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin. | 2021 Sep 11 |
1 |
| 3 |
22584460 | Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin. | 2013 Aug |
1 |
| 4 |
20858843 | Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. | 2010 Nov 1 |
1 |
| 5 |
19446624 | pH-sensitive immunoliposomes specific to the CD33 cell surface antigen of leukemic cells. | 2009 Nov 3 |
1 |
| 6 |
18854573 | Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia. | 2008 Nov 10 |
1 |
| 7 |
15676214 | Anti-CD33 monoclonal antibodies enhance the cytotoxic effects of cytosine arabinoside and idarubicin on acute myeloid leukemia cells through similarities in their signaling pathways. | 2005 Feb |
4 |